Regenerative biotechnology
Autologous Natural Killer Cells Blockade
Autologous Natural Killer cells pretreated with dual immune checkpoint blockade for antitumor therapy.
Therapy composed of seven million autologous Natural Killer cells pretreated with nivolumab and ipilimumab, optimizing the innate and adaptive immune response against tumor cells.
Composition
Autologous Natural Killer cells, nivolumab, ipilimumab.
Pharmaceutical form
Injectable solution.
Presentation
Monovette with 4 ml.
Therapeutic Properties
Targeted cytotoxic activity through pretreated autologous NK cells that strengthen the antitumor immune response and optimize the identification of malignant cells.
- Recognition of tumor cells.
- Induction of tumor apoptosis.
- Blockade of immune evasion.
- Increase in antitumor cytotoxicity.
- Innate immune activation.
- Enhancement of adaptive T lymphocytes.
- Reduction of active tumor growth.
- Functional optimization of the immune system.
Mechanism of action & Clinical data
Activated autologous NK cells modulated with dual immune checkpoint blockade restore the cytotoxic capacity of the immune system and promote tumor elimination.